Vivitrol and Vyleesi Injection

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.GENERALLY AVOID: Bremelanotide may significantly decrease the bioavailability of orally administered naltrexone. Because bremelanotide can slow gastric motility, it may reduce the rate and extent of absorption of concomitantly administered oral medications. In clinical pharmacology studies, bremelanotide 1.75 mg given subcutaneously did not affect the absorption of most of the tested oral medications to any clinically relevant degree. However, naltrexone peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by approximately 60% and 40%, respectively, relative to administration alone. MANAGEMENT: The prescribing information for bremelanotide recommends avoiding concomitant use with orally administered naltrexone-containing products that are intended for the treatment of alcohol or opioid addiction. When naltrexone is used for other indications, monitor for potentially reduced therapeutic efficacy when coadministered with bremelanotide. References "Product Information. Vyleesi (bremelanotide)." AMAG Pharmaceuticals Inc, Lexington, MA.

GENERALLY AVOID: Bremelanotide may significantly decrease the bioavailability of orally administered naltrexone. Because bremelanotide can slow gastric motility, it may reduce the rate and extent of absorption of concomitantly administered oral medications. In clinical pharmacology studies, bremelanotide 1.75 mg given subcutaneously did not affect the absorption of most of the tested oral medications to any clinically relevant degree. However, naltrexone peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by approximately 60% and 40%, respectively, relative to administration alone.

MANAGEMENT: The prescribing information for bremelanotide recommends avoiding concomitant use with orally administered naltrexone-containing products that are intended for the treatment of alcohol or opioid addiction. When naltrexone is used for other indications, monitor for potentially reduced therapeutic efficacy when coadministered with bremelanotide.

Vivitrol

Generic Name: naltrexone

Brand name: Vivitrol, Depade, ReVia

Synonyms: n.a.

What is Vivitrol?

Vyleesi Injection

Generic Name: bremelanotide

Brand name: Vyleesi

Synonyms: Vyleesi

What is Vyleesi Injection?